Their data from 68 patients support our findings as AGR2 expression reported in GEO showed a significantly higher average expression levels in grade (II+) tumors/or tumors that reoccurred compared to grade I tumours (grade I: 104.285, grade II+/reoccurred: 988.182, T test P 0.021). Here, AGR2 is linked to neoplasm.